Company Overview - CollPlant Biotechnologies is a regenerative and aesthetics medicine company focused on developing innovative technologies and products based on non-animal-derived rhCollagen for tissue regeneration and medical aesthetics [1][2] - The company specializes in 3D bioprinting of tissues and organs, tissue repair, and medical aesthetics, utilizing proprietary plant-based genetic engineering technology to produce rhCollagen [2] Financial Reporting - CollPlant will report its financial results for the third quarter of 2025 on November 26, 2025, before the opening of U.S. financial markets [1] Strategic Partnerships - In 2021, CollPlant entered into a development and global commercialization agreement for dermal and soft tissue fillers with Allergan, a subsidiary of AbbVie and a leader in the dermal filler market [3]

Core Insights - FibroBiologics, Inc. is a clinical-stage biotechnology company focused on developing therapeutics for chronic diseases using fibroblasts and fibroblast-derived materials, holding over 240 patents [1][5] - The company presented research on a scalable artificial thymus organoid at the ThymUS 2025 Meeting, which aims to recover the functionality of the thymus [2][3] Company Overview - Founded in 2001, FibroBiologics is based in Houston and is engaged in developing a pipeline of treatments for various chronic diseases, including multiple sclerosis, cancer, and wound healing [5] - The company emphasizes the unique immunomodulatory properties of fibroblasts, which are believed to enhance the functionality and durability of therapeutic organoids [3][5] Research and Development - The presented abstract details a method for developing transplantable and scalable thymus organoids that can generate functional T cells, indicating significant progress in the field [2][3] - The research highlights the potential of organoids to transform the study and treatment of chronic diseases, showcasing the innovative approaches being explored by the company [3]